Table 2

 Mean (SEM) change in DAS28, mean (SEM) change in the number of intimal lining CD68+ macrophages, mean (SEM) change in the number of sublining CD68+ macrophages, and the mean percentage change in sublining CD68+ macrophages compared with baseline for each substudy

TreatmentChange in the number of intimal lining CD68+ macrophagesChange in the number of sublining CD68+ macrophagesChange for sublining CD68+ macrophagesChange in DAS28
(No; interval)Mean (SEM)Mean (SEM)Mean %Mean (SEM)
Prednisolone start (10; 14)−35 (46)−492 (89)−51−2.15 (0.40)
Infliximab (Remicade) (20; 28)−100 (30)−275 (84)−47−1.39 (0.28)
Leflunomide start (15; 112)−28 (17)−286 (112)−38−1.29 (0.31)
Methotrexate start (15; 112)−44 (17)−292 (106)−41−1.36 (0.25)
CCR1 antagonist (10; 14)−192 (81)−338 (131)−44−0.72 (0.27)
Stable DMARD (12; 14)+40 (38)+152 (107)+ 13−0.23 (0.10)
Stable MTX (6; 2)−71(29)+26 (158)+ 22+0.07 (0.28)
Active treatment grouped (70; 53)−76 (17)−321 (46)−44−1.37 (0.14)
Controls grouped (18; 10)+3 (29)+110 (87)+ 17−0.13 (0.12)